Brought to you by 
Bio-Techne pays $250mm plus earn-outs to buy Exosome Diagnostics
18 Sep 2020
Executive Summary
Bio-Techne Corp. will pay $250mm to acquire privately held biofluid-based diagnostics firm Exosome Diagnostics Inc. The deal also includes up to $325mm in earn-outs based on achievement of certain EBITDA targets in 2020 and 2022.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bio-Techne pays $250mm plus earn-outs to buy Exosome Diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice